Given the urgent need for an preventive Ebola vaccine strategy in the context of the current epidemic, the clinical development plan follows an expedited scheme, aiming at starting a Phase 2B large scale safety and immunogenicity study as soon as possible while assuring the safety of the trial participants.

Phase 1 trials to assess the safety and immunogenicity data of the candidate prime-boost regimen in healthy volunteers are ongoing in the UK, the US and Kenya and Uganda. A further study site has been approved to start in Tanzania. Both prime-boost combinations (Ad26.ZEBOV prime + MVA-BN-Filo boost; and MVA-BN-Filo prime + Ad26.ZEBOV boost) administered at different intervals are being tested in these trials. 

Phase 2 trials (this project) are planned to start as soon as the post-prime safety and immunogenicity data from the UK Phase I are available. Phase 2 trials will be conducted in healthy volunteers in Europe (France and UK) and non-epidemic African countries (to be determined). HIV positive adults will also be vaccinated in African countries. The rationale for inclusion of European volunteers in Phase 2, in addition to the trials in Africa, is to allow for higher sensitivity in safety signal detection in populations with low incidence of febrile illnesses, to generate negative control specimens for assay development, to allow for inclusion of health care workers or military personnel that may be deployed to Ebola-endemic regions.

News

  • 27 October 2017

    The 3rd EBOVAC2 Newsletter is now available here. Our October 2017 issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz site.

  • 12 September 2017

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018 Registration - Enregistrement

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 27 June 2017

    The 2nd EBOVAC2 newsletter June 2017 is now available here!

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research